Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

EastWest Bioscience Inc V.EAST.H

EastWest Bioscience Inc. is a Canada-based vertically integrated wellness company with a multitude of business units and assets that allow for seed-to-sale supply chain management. The Company sources its raw materials, processes, manufactures, tests, brands, markets, and distributes its products to its customers in Canada, the United States and others. It owns and operates retail and manufacturing subsidiaries. Its retail subsidiary (natural health retail franchise - the Sangster's health centers) is engaged in the health and wellness industry. Its stores provide natural remedies for the prevention and treatment of disease and ailments. It has over 202 exclusively labeled products, including vitamins, mineral, herbs, proteins, natural body care and organic foods. The Company, through its subsidiary, Orchard Vale Naturals Inc., is a Health Canada licensed manufacturing facility with capabilities to encapsulate, package and label. It manufactures health supplements for B2B clients.


TSXV:EAST.H - Post by User

Post by OneTwoOneTwoon Jan 30, 2020 10:02am
63 Views
Post# 30619295

Last paragraph of Section 1 of audited financials

Last paragraph of Section 1 of audited financials
However, the Company had not yet achieved profitable operations. For the year ended July 31, 2019, the Company incurred a net loss of $3,649,066 and had an accumulated deficit of $8,184,397 and expects to incur further losses in the development of its business, all of which casts significant doubt about the Company’s ability to continue as a going concern.

Looking great Rod. No scam here. lol
<< Previous
Bullboard Posts
Next >>